Beat The Denominator

The recent 20% price drop in AI beauty tech company Auditi (ODD) is viewed as an unwarranted buying opportunity for a profitable, fast-growing business. Similarly, telehealth company LifeMD (LFMD) is considered heavily undervalued after a 44% sell-off to around $6 per share. This drop is seen as a clear overreaction to temporary GLP-1 drug strategy issues, creating a compelling entry point. The market is ignoring LFMD's diversified and growing underlying business in mental health and other segments. For those bullish on the Buy Now, Pay Later theme, Sezzle (SEZL) is presented as the cheapest and fastest-growing option in the sector following its recent stock decline.

MicroStrategy (MSTR) is presented as a top investment idea, positioned for a potential short squeeze now that the company has paused issuing new shares. The stock is viewed as a leveraged play on Bitcoin that has historically outperformed, returning 31x over five years versus Bitcoin's 7x. This bullish thesis is supported by Bitcoin (BTC) recently surging past $119,000. For an alternative value play, consider MicroStrategy's preferred stocks, which are expected to rise if interest rates are cut in September. Specifically, the convertible preferred stock STRIKE is highlighted as an opportunity after its recent price drop to around $109.

Cormedix (CRMD) is presented as a strong buy, with its recent price drop viewed as a gift for investors before its acquisition of Melinta Therapeutics adds significant revenue. Oscar Health (OSCR) is another deeply undervalued turnaround play, with planned double-digit price increases expected to drive profitability next year. For long-term growth, consider Hims & Hers (HIMS) as it expands into massive new markets like hormone health and longevity. Patient investors may also find an opportunity in Delcath Systems (DCTH), which has fallen in price despite strong execution and holds significant long-term potential from its cancer treatment pipeline. These healthcare stocks are seen as undervalued due to market overreactions rather than poor company performance.

Consider buying The Real Brokerage (REAX), as its recent post-earnings stock drop is viewed as an irrational buying opportunity. This asset-light company is a long-term play on the eventual recovery of the real estate market, potentially by May 2026. In contrast, The Trade Desk (TTD) is a name to watch after its significant price drop, but it is not yet a buy at current levels. The business fundamentals for TTD remain strong, and it becomes an attractive purchase if the stock falls another 10-15%. Therefore, investors should consider setting a price alert for TTD while evaluating a position in REAX.

Nebius (NBIS) is a high-conviction investment opportunity in the AI Cloud space, demonstrating hyper-growth with 624% year-over-year revenue growth. The company has raised its revenue run-rate guidance to $1.1 billion by the end of 2025, signaling strong future performance. A key part of the investment thesis is its "hidden value" from a 28% stake in data analytics firm ClickHouse and ownership of autonomous vehicle company AVRide. Analysts suggest NBIS is attractively valued, potentially offering a better risk/reward profile than Super Micro Computer (SMCI). The combination of explosive core business growth, new high-profile customers like Cloudflare (NET), and undervalued assets makes NBIS a compelling consideration.

Celsius Holdings (CELH) is a high-conviction investment opportunity due to its strong earnings, rapid growth, and successful acquisition of the Alani brand. The company is gaining significant market share from competitors like Monster (MNST) by appealing to a broader, less-saturated consumer base. With impressive gross margins near 52% and organic growth of 41%, CELH is considered a highly profitable "cash machine." Analysts view the stock as "cheap for quality" given its forward growth prospects of over 35%. Future catalysts include international expansion, positioning CELH for long-term growth in the expanding energy drinks sector.

Delcath Systems (DCTH) is presented as a high-risk, high-growth opportunity in liver cancer treatment, with its recent sell-off viewed as a buying opportunity given its exceptionally low valuation. TG Therapeutics (TGTX) is another high-conviction idea, considered poised to bounce after a recent 20% drop due to strong market share gains for its Multiple Sclerosis drug within a protected market. Management at TGTX has also raised guidance and expects a significantly stronger second half of the year, providing a potential near-term catalyst. In the beauty sector, consider avoiding e.l.f. Beauty (ELF) due to slowing growth and margin pressure from tariffs. Instead, Oddity Tech (ODD) is highlighted as a preferred alternative with higher margins and a direct-to-consumer business model.

The recent drop in Super Micro Computer (SMCI) is presented as a significant buying opportunity due to a market overreaction. As a leading pure-play in liquid cooling, the company is a critical supplier for the next generation of powerful AI chips from partners like NVIDIA. The stock is considered undervalued, trading at a significant discount to peers like AMD on a forward sales basis. This positions SMCI as a key "picks and shovels" investment to capitalize on the buildout of AI infrastructure. For direct exposure to this high-growth theme, SMCI is presented as a more focused investment than diversified competitors like Dell (DELL).

In the telehealth sector, Hims & Hers (HIMS) is presented as the superior investment right now due to its more stable cash-pay business model. This model avoids the significant risk of insurance claim denials that is currently hurting competitor LifeMD (LFMD) in the popular GLP-1 weight-loss drug market. LFMD recently experienced a sharp stock drop after cutting its revenue guidance, highlighting the challenges in its business. With a stronger guided revenue growth of 45%, HIMS offers a more predictable and robust outlook. A key potential catalyst for LFMD to watch for is the sale of its slow-growing legacy business, WorkSimply.

Consider buying shares of Oddity (ODD), as its recent -22% price drop appears disconnected from its strong financial performance and raised future guidance. The company's AI-powered, direct-to-consumer business model drives superior profit margins and customer loyalty, making it a more compelling investment than competitor ELF. ODD is growing revenue over 20% and is set to launch a new dermatology brand in the second half of the year, providing a potential future catalyst. Management also has a $103 million share buyback program in place, which could support the stock price at these lower levels. Adding a high-growth name like ODD can provide valuable diversification for portfolios concentrated in other sectors.

Hims & Hers Health (HIMS) is a long-term investment focused on becoming a leader in preventative and personalized healthcare. The stock appears significantly undervalued based on its 2030 financial targets, making the recent price drop a potential entry point for investors. Key growth drivers to watch are the expansion of personalized GLP-1 weight loss treatments, the launch of a new lab testing business, and the introduction of menopause therapies. A major future catalyst is the planned launch of generic semaglutide in Canada in early 2026. One analyst noted they would consider buying more shares of HIMS under $50.

The recent stock price drop in Hims & Hers Health (HIMS) presents a potential long-term buying opportunity for investors. Despite short-term market concerns, the company's fundamental growth in revenue and subscribers remains strong. Future growth is expected from the launch of a new longevity product line and expansion into Hormone Replacement Therapy (HRT). The company is also beginning its international expansion into Canada, starting with its weight loss offerings. These catalysts support a bullish long-term outlook, suggesting the core investment thesis is as strong as ever.

For long-term growth, consider holding MSTR common stock as a leveraged play on Bitcoin, using the "Buy-Borrow-Die" strategy to generate tax-free income by borrowing against your shares. This high-conviction strategy is dependent on Bitcoin's appreciation, with speculation that a $200,000 BTC price could double MSTR's value. For stable, tax-efficient retirement income, MSTR's preferred stocks can provide qualified dividends that are potentially tax-free for retirees. The preferred stock STRF is highlighted for its high, stable yield, while Strike is noted as a good value for those wanting some Bitcoin upside. A powerful approach is to combine both, using preferred stock dividends for living expenses and borrowing against the common stock for larger purchases.

For investors seeking diversification, consider uncorrelated opportunities in consumer goods, energy, and specialized tech. SharkNinja (SN) is a fast-growing consumer brand with strong margins, offering a stable holding that is still considered undervalued. For a value play in the energy sector, Tidewater (TDW) has pulled back recently, presenting an attractive entry point to capitalize on the supply shortage of offshore service vessels. For those with a higher risk tolerance, the Kazakhstani super-app Kaspi (KSPI) is a contrarian opportunity, as the stock is down due to expansion uncertainty despite its massive profitability. Finally, Gambling.com (GAMB) offers a cheap, high-margin "picks and shovels" way to invest in the growing online betting trend without direct operator risk.

The recent market-driven drop in MicroStrategy (MSTR) presents a potential buying opportunity for long-term investors. A key bullish catalyst is the company's decision to halt new share offerings until the stock price surpasses $600, protecting current shareholders from dilution. Significant insider buying from board members signals strong conviction that the stock is currently undervalued. As a leveraged play on Bitcoin (BTC), the company's success is tied to the asset, which has a conservative price target of $150,000 by the end of 2025. Based on the company's own valuation models, MSTR stock could have a potential 6x return from its current levels.

MicroStrategy (MSTR) presents a compelling investment opportunity following significant positive updates to its corporate strategy. The company has effectively paused its share issuance program, which could allow the stock to rise 30-40% before selling pressure from new shares resumes. Furthermore, MSTR raised its full-year 2025 Bitcoin (BTC) yield target to an impressive 30%, aiming to significantly grow its crypto holdings. This high yield offers a way to outperform holding Bitcoin directly, helping to justify the stock's premium valuation. For investors seeking enhanced Bitcoin exposure, MSTR provides a clear strategy for appreciation and yield generation.

Consider buying Bitcoin (BTC) or MicroStrategy (MSTR) near the end of the U.S. trading day to potentially capitalize on a recurring daily price dip. For investors interested in the telehealth sector, LifeMD (LFMD) is presented as a more attractive and cheaper alternative to Hims & Hers Health (HIMS) at current valuations. Investors are advised to be cautious about adding to HIMS near its all-time high, as it may be due for a pullback. Similarly, the investment opportunity in Figma was at its IPO price, and it is no longer considered an attractive buy at its current elevated price. This leaves LFMD as the primary "buy" recommendation from these insights.

Consider an investment in Marathon Digital (MARA), as it trades at a valuation nearly equal to the Bitcoin it holds, essentially offering its large-scale mining operation for free. This is a higher-risk, higher-reward play due to the company's strategy of lending out its Bitcoin and issuing new shares to fund operations. The success of this investment is fundamentally tied to a rising price for Bitcoin (BTC), which is the primary catalyst. For investors seeking a lower-risk alternative, MicroStrategy (MSTR) is positioned as a "blue chip" that simply holds Bitcoin without the added operational risks.

The recent pullback in MicroStrategy (MSTR) presents a significant buying opportunity, as the company continues its aggressive strategy of accumulating Bitcoin. A recent purchase of 21,021 Bitcoin at an average price of ~$117k demonstrates strong institutional conviction at these levels. Investors could consider taking profits on more speculative, "higher octane" Bitcoin-related stocks that may be overvalued. It is recommended to reinvest those gains into MSTR, which is viewed as the "blue chip" leader in the Bitcoin treasury sector. The long-term bull case is tied to Bitcoin's potential to reach $1 million, which would position MSTR as a potential trillion-dollar company.

For Bitcoin exposure, Marathon Digital (MARA) is a compelling value play, trading near its net asset value. This is a clear, actionable idea for investors bullish on crypto. Finally, SoFi (SOFI) is a long-term growth story with clear catalysts. I'm crafting a concise,